Please assess the completion status of the following clinical trial:

Trial Title: Study of Modified Process Hib/Hep B Vaccine in Infants (V121-019)(COMPLETED)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy 2-month-old full term infants born to non-HBs Ag (hepatitis B virus) carrier mothers~Exclusion Criteria:~* Birth mother known to be a carrier of hepatitis B virus (HBsAg+) or known carriers ever living in close contact with the subject~* History of previous hepatitis B infection; history of vaccination with any hepatitis B vaccine~* Recent (\<72 hours) history of febrile illness (rectal temperature \>=38.1°C/\>=100.5°F)~* Known or suspected hypersensitivity to any component of RECOMBIVAXHB™ or COMVAX™ (e.g., aluminum, yeast)~* Recent administration (w/i 3 months prior to study start) of hepatitis B immune globulin (HBIg), serum immune globulin, or any other blood-derived product~* Receipt of investigational drugs or investigational vaccines within 3 months prior to study start or if planned within the study period;~* Known or suspected impairment of immunologic function or recent use (within 3 months prior to study start) of immunomodulatory medications (does not include topical and inhaled steroids);~* Any condition that, in the opinion of the investigator, might interfere with the evaluation of study objectives; or inability to comply with the study schedule and/or inability to attend all required study visits

- Gender: ALL
- Minimum Age: 40 Days
- Maximum Age: 80 Days
- Healthy Volunteers: t

Study Arms:
- 1 (Type: EXPERIMENTAL): Modified process Hib/Hep B vaccine
- 2 (Type: ACTIVE_COMPARATOR): COMVAX™

Based on this trial design, predict the completion outcome and termination type (if applicable).